J. Edward Dulac's Insider Trades & SAST Disclosures
J. Edward Dulac's most recent trade in Intellia Therapeutics Inc was a trade of 67,429 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern J. Edward Dulac.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | Edward J. Dulac | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 67,429 | 67,429 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Edward J. Dulac | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 47,200 | 113,524 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | Edward J. Dulac | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 96,219 | 96,219 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | Edward J. Dulac | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 66,324 | 66,324 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.77 per share. | 04 Mar 2024 | 2,447 | 101,479 (0%) | 0% | 7.8 | 19,013 | Common Stock |
| Fate Therapeutics Inc | J. Edward Dulac | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 425,000 | 425,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | J. Edward Dulac | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 5.00 per share. | 29 Jan 2024 | 1,849 | 103,926 (0%) | 0% | 5 | 9,245 | Common Stock |
| Fate Therapeutics Inc | J. Edward Dulac | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.37 per share. | 09 Jan 2024 | 7,028 | 105,775 (0%) | 0% | 4.4 | 30,712 | Common Stock |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.66 per share. | 02 Jan 2024 | 5,182 | 112,803 (0%) | 0% | 3.7 | 18,966 | Common Stock |
| Fate Therapeutics Inc | J. Dulac Edward | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.50 per share. | 18 Dec 2023 | 1,585 | 117,985 (0%) | 0% | 3.5 | 5,548 | Common Stock |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.80 per share. | 18 Aug 2023 | 4,718 | 119,570 (0%) | 0% | 2.8 | 13,210 | Common Stock |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.83 per share. | 05 Jul 2023 | 5,182 | 124,288 (0%) | 0% | 4.8 | 25,029 | Common Stock |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 425,000 | 425,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 5.24 per share. | 10 Jan 2023 | 7,331 | 129,470 (0%) | 0% | 5.2 | 38,414 | Common Stock |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 53,058 | 53,058 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 33,302 | 141,936 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 48.25 per share. | 11 Jan 2022 | 1,380 | 109,024 (0%) | 0% | 48.3 | 66,585 | Common Stock |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 49.16 per share. | 11 Jan 2022 | 390 | 108,634 (0%) | 0% | 49.2 | 19,172 | Common Stock |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 59,540 | 111,944 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 62.53 per share. | 28 Sep 2021 | 19,460 | 52,404 (0%) | 0% | 62.5 | 1,216,834 | Common Stock |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Sep 2021 | 17,325 | 142,675 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.52 per share. | 28 Sep 2021 | 17,325 | 71,864 (0%) | 0% | 35.5 | 615,384 | Common Stock |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 87.90 per share. | 19 Aug 2021 | 1,937 | 56,076 (0%) | 0% | 87.9 | 170,262 | Common Stock |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 88.65 per share. | 19 Aug 2021 | 1,474 | 54,602 (0%) | 0% | 88.6 | 130,670 | Common Stock |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 19 Aug 2021 | 63 | 54,539 (0%) | 0% | 90 | 5,670 | Common Stock |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2021 | 18,013 | 58,013 (0%) | 0% | 0 | Common stock | |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2021 | 6,851 | 6,851 | - | - | Stock Option (right to buy) | |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2020 | 160,000 | 160,000 | - | - | Stock Option (right to buy) | |
| Fate Therapeutics Inc | Edward J. Dulac | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2020 | 40,000 | 40,000 (0%) | 0% | 0 | Common stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges